Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) has been given an average rating of “Hold” by the six brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.00.

A number of analysts have commented on the company. HC Wainwright set a $4.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Friday, November 17th. ValuEngine cut Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, Canaccord Genuity set a $7.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research report on Wednesday, November 15th.

Shares of Aptose Biosciences (NASDAQ:APTO) traded up $0.11 on Friday, reaching $3.72. The company’s stock had a trading volume of 533,757 shares, compared to its average volume of 461,531. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $3.90. The firm has a market cap of $90.98, a PE ratio of -6.02 and a beta of 2.50.

An institutional investor recently raised its position in Aptose Biosciences stock. Acadian Asset Management LLC raised its stake in shares of Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 44,421 shares of the biotechnology company’s stock after buying an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/03/14/analysts-set-aptose-biosciences-inc-apto-price-target-at-6-00.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.